Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)- resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

European Journal of Cancer

Volumn 36, Issue 15, 2000, Pages 1974-1983

  Bergman, A M ^a   Giaccone, G ^a   Van Moorsel, C J A ^a   Mauritz, R ^a   Noordhuis, P ^a   Pinedo, H M ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cross resistance; Deoxyguanosine kinase activity (DGK); DNA damage; DT diaphorase activity (DTD); Folylpolyglutamate synthetase (FPGS) activity; Gemcitabine; Glutathione; Methotrexate polyglutamination; Methotrexate uptake; Topoisomerase

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE DERIVATIVE; CYTARABINE; DAUNORUBICIN; DEOXYGUANOSINE KINASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; GLUTATHIONE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NOLATREXED; PACLITAXEL; RALTITREXED; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRIMETREXATE; TRITIUM; UNINDEXED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CROSS RESISTANCE; DNA DAMAGE; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033800910     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00246-X     Document Type: Article

References (67)

1. L.W. Hertel G.B. Boder J.S. Kroin Evaluation of the antitumor activity of a (2′,2′-difluoro-2′-deoxycytidine) Cancer Res. 50 1990 4417 4422
2. E. Boven H. Schipper C.A.M. Erkelens S.A. Hatty H.M. Pinedo The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer Br. J. Cancer 68 1993 52 56
3. C.J.A. Van Moorsel G.J. Peters H.M. Pinedo Cemcitabine prospects of single-agent and combination studies The Oncologist 2 1997 127 134
4. B. Lund O.P. Hansen K. Theilade M. Hansen J.P. Neijt Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
5. A.M. Bergman V.W.T. Ruiz van Haperen G. Veerman C.M. Kuiper G.J. Peters Synergistic interaction between cisplatin and gemcitabine in vitro Clin. Cancer Res. 2 1996 521 530
6. G.J. Peters V.W.T. Ruiz van Haperen A.M. Bergman Preclinical combination therapy with gemcitabine and mechanisms of resistance Semin. Oncol. 23 5 Suppl. 10 1996 16 24
7. G.J. Peters S.P. Ackland New antimetabolites in preclinical and clinical development Exp. Opin. Invest. Drugs 5 1996 637 679
8. R.P. Abratt A. Sandler L. Crino Combined cisplatin and gemcitabine for non-small cell lung cancer influence of scheduling on toxicity and drug delivery Semin. Oncol. 25 4 Suppl. 9 1998 35 43
9. V.W.T. Ruiz van Haperen G. Veerman J.B. Vermorken G.J. Peters 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines Biochem. Pharmacol. 46 1993 762 766
10. P. Huang S. Chubb L.W. Hertel G.B. Grindey W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res. 51 1991 6110 6117
11. V. Heinemann L.W. Hertel G.B. Grindey W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β- d -arabinofuranosylcytosine Cancer Res. 48 1988 4024 4031
12. V. Heinemann Y.-Z. Xu S. Chubb Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate a mechanism of self potentiation Cancer Res. 52 1992 533 539
13. V. Heinemann Y.-Z. Xu S. Chubb Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol. Pharmacol. 38 1990 567 572
14. Ruiz van Haperen VWT, Veerman G, Smid K, Pinedo HM, Peters GJ. Gemcitabine inhibits thymidylate synthase (TS) activity in solid tumour cell lines. Proc Am Assoc Cancer Res 1995, 36 , 354 (abstract 2107).
15. Heinemann V, Plunkett W. Inhibitory action of 2′,2′-difluorodeoxycytidine (dFdC) on cytidine 5′-triphosphate synthase. Ann Oncol 1992, 3 (Suppl. 1), 187 (abstract 510).
16. E. Smitskamp-Wilms H.M. Pinedo G. Veerman V.W.T. Ruiz van Haperen G.J. Peters Postconfluential multilayered cell line cultures for selective screening of gemcitabine Eur. J. Cancer 34 1998 921 926
17. V.W.T. Ruiz van Haperen G.J. Peters New targets for pyrimidine antimetabolites for the treatment of solid tumours. II. Deoxycytidine kinase Pharm. World Sci. 16 1994 104 112
18. Momparler RL, Onetto-Pothier N. Drug resistance to cytosine arabinoside. In Kessel D, ed. Resistance to Antineoplastic Drugs . CRC Press, 1989, 353–367.
19. J.R. Mackey R.S. Mani M. Selner Functional nucleoside transporters are required for gemcitabine influx and manifestations of toxicity in cancer cell lines Cancer Res. 58 1998 4349 4357
20. Goan Y-G, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2′,2′-difluorodeoxycytidine in a human KB cancer cell line. Proc Am Cancer Res 1999, 40 , 678 (abstract 4473).
21. C. Dumontet K. Fabianowska-Majewska D. Mantincic Common resistance mechanisms to deoxynucleoside analogs in variants of the human erythroleukemic line K562 Br. J. Haematol. 106 1999 78 85
22. S.A. Cannistra Cancer of the ovary N. Engl. J. Med. 329 1993 1550 1559
23. S.W. Johnson R.E. Ozols T.C. Hamilton Mechanisms of drug resistance in ovarian cancer Cancer 71 1993 644 649
24. V.W.T. Ruiz van Haperen G. Veerman S. Eriksson Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780 Cancer Res. 54 1994 4138 4143
25. Y. Lu J. Han K.J. Scanlon Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid J. Biol. Chem. 263 1988 4891 4894
26. P. Skehan R. Storeng D. Scudiero New calorimetric cytotoxicity assay for anticancer drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
27. Y.P. Keepers P.E. Pizao G.J. Peters Comparison of the sulforhodamine B Protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing Eur. J. Cancer 27A 1991 897 900
28. G.J. Peters M. Wets Y.P. Keepers Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism Int. J. Cancer 54 1993 450 455
29. H.C. Birnboim J.J. Jevcak Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation Cancer Res. 41 1981 1889 1892
30. M.M. Bradford A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
31. H.J. Prochaska P. Talalay Purification and characterization of two isofunctional forms of NAD(P)H quinone reductase from mouse liver J. Biol. Chem. 261 1986 1372 1378
32. L. Ernster DT diaphorase Meth. Enzymol. 10 1967 309 317
33. E. Smitskamp-Wilms G.J. Peters H.M. Pinedo J. van Ark-Otte G. Giaccone Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression Biochem. Pharmacol. 47 1994 1325 1332
34. G.J. Peters A. Oosterhof J.H. Veerkamp Adenosine and deoxyadenosine metabolism in mammalian lymphocytes Int. J. Biochem. 13 1981 445 455
35. G.J. Peters A. Oosterhof J.H. Veerkamp Metabolism of purinenucleosides in human and ovine lymphocytes and rat thymocytes and their influence on mitogenic stimulation Biochim. Biophys. Acta. 755 1983 127 136
36. E.S. Arner T. Spasokoukotskaja S. Eriksson Selective assays for thymidine kinase 1 and deoxycytidine kinase and their activitiesin extracts from human cells and tissues Biochim. Biophys. Res. Commun. 188 1992 712 718
37. N. Feller C.M. Kuiper J. Lankelma Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by cytometry Br. J. Cancer 72 1995 543 549
38. H.S. Mulder J. Lankelma H. Dekker H.J. Broxterman H.M. Pinedo Daunorubicin efflux against a concentration gradient in non-P–glycoprotein multidrug resistance lung-cancer cells Int. J. Cancer 59 1994 275 281
39. B.J.M. Braakhuis G. Jansen P. Noordhuis A. Kegel G.J. Peters Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma Biochem. Pharmacol. 46 1993 2155 2161
40. G. Jansen G.R. Westerhof M.J. Jarmuszewski Methotrexate transport in variant CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates J. Biol. Chem. 265 1990 18272 18277
41. G. Jansen J.H. Schornagel I. Kathmann Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure Oncol. Res. 7 1992 299
42. L. Slordal A. Andersen L. Dajani D.J. Warren A simple HPLC method for the determination of cellular glutathione Pharmacol. Toxicol. 73 1993 124 126
43. P. Pizao E. Smitskamp-Wilms J. Van Ark-Otte Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures Biochem. Pharmacol. 48 1994 1145 1154
44. V. Gandhi S. Mineishi P. Huang Difluorodeoxyguanosine cytotoxicity, metabolism and actions on DNA synthesis in human leukemia cells Semin. Oncol. 22 4 Suppl. 11 1995 61 67
45. V. Gandhi S. Mineishi P. Huang Cytotoxicity, metabolism and mechanisms of action of 2′,2′-difluorodeoxy-guanosine in chinese hamster ovary cells Cancer Res. 55 1995 1517 1524
46. Van Moorsel CJA, Lakerveld B, Smid K, et al. Effects of gemcitabine (dFdC) on formation and repair of platinum (Pt)–DNA adducts in ovarian cancer cell lines. Proc Am Assoc Cancer Res 1999, 40 , 590 (abstract 5889).
47. F.M. Sirotnak D.M. Moccio L.J. Goutas L.E. Kelleher J.A. Montgomery Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate metoprine Cancer Res. 42 1982 924 930
48. Y. Takemura H. Kobayashi W. Gibson The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells Int. J. Cancer 66 1996 29 36
49. S.B. Horwitz D. Cohen S. Rao Taxol mechanisms of action and resistance NCI Monogr. 15 1993 55 61
50. M. Kavallaris D.Y.S. Kuo C.A. Burkhart Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific B-tubulin isotypes J. Clin. Invest. 100 5 1997 1282 1293
51. T. Andoh K. Ishii Y. Suzuki Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I Proc. Natl. Acad. Sci. USA 84 1987 5565 5569
52. Y. Kawato M. Aonuma Y. Hirota H. Kuga K. Sato Intracellular roles of SN38. a metabolite of the campotothecin derivate CPT-11, in the anti-tumor effect of CPT-11 Cancer Res. 51 1991 4187 4191
53. D. Hochhauser A.L. Harris The role of topoisomerase IIα and β in drug resistance Cancer Treat. Rev. 19 1993 181 194
54. B. Goz K.F. Bastow A possible role for topoisomerase II in cell death and N-phosphonoacetyl- l -aspartate-resistance frequency and its enhancement by 1-β- d -arabinofuranosyl cytosine and 5-fluoro-2′-deoxyuridine Mutat. Res. 384 1997 89 106
55. S.M. Simon M. Shindler Cell biological mechanisms of multidrug resistance in tumors Proc. Natl. Acad. Sci. USA 91 1994 3497 3504
56. A.A. Hindenburg J.E. Gervasoni Jr. S. Krishna Intra cellular distribution and pharmacokinetics of daunorubicine in anthracycline sensitive and resistant HL60 cells Cancer Res. 49 1989 4607 4614
57. L.V. Johnson M.L. Walsh B.J. Bockus L.B. Chen Monitoring of relative mitochondrial potential in living cells by fluorescence microscopy J. Cell. Biol. 88 1981 526
58. P.R. Twentyman T. Rhodes S.A. Rayner Comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes Eur. J. Cancer 30A 1994 1360 1369
59. Z. Holló L. Homolya C.W. Davis B. Sarkadi Calcein accumulation as a fluorometric functional assay of the multidrug transporter Biochim. Biophys. Acta. 1191 1994 384 388
60. S.W. Johnson P.A. Swiggard L.M. Handel Relationship between platinum–DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Res. 54 1994 5911 5916
61. T. Ishikawa F. Ali-Osman Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells J. Biol. Chem. 268 1993 20116 20125
62. A.K. Godwin A. Meister P.J. O'Dwyer High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc. Natl. Acad. Sci. USA 89 1992 3070 3074
63. S.W. Johnson P.B. Laub J.S. Beesley R.F. Ozols T.C. Hamilton Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Res. 57 1997 850 856
64. J.R. Warr G.F. Atkinson Genetic aspects of resistance to anticancer drugs Physiol. Rev. 68 1988 1 26
65. B. Windle B.W. Draper Y. Yin S. O'Gorman G.M. Wahl A central role for chromosome breakage in gene amplification, deletion formation and amplicon integration Genes Dev. 5 1991 160 174
66. Y.S. Bae I. Kawasaki H. Ikeda L.F. Liu Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro Proc. Natl. Acad. Sci. USA 85 1988 2076 2080
67. C. Holm T. Stearns D. Botstein DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage Mol. Cell. Biol. 9 1989 159 168